Tag: Saxagliptin

The brand-name diabetes drug Onglyza was officially discontinued by its manufacturer, AstraZeneca, as a business decision, not for safety concerns. Despite this, patients no longer need to rely on the brand-name product because there is a generic version of Onglyza now widely available.

Despite both being used to treat type 2 diabetes and belonging to the same drug class, Onglyza (saxagliptin) and Januvia (sitagliptin) are not the same medication. These two DPP-4 inhibitors share a similar goal of controlling blood sugar but differ significantly in their active ingredients, potency, and safety profiles.

For many patients with type 2 diabetes, managing blood sugar without significant weight gain is a primary concern. The question, **Does the DPP-4 inhibitor cause weight gain?**, is often asked, and studies generally indicate these medications have a weight-neutral effect or, in some cases, result in modest weight loss.

As of 2020, approximately 1.5 million people in the US were prescribed Onglyza (saxagliptin) for Type 2 diabetes. If you are looking for information on **what drug is comparable to Onglyza**, understanding its drug class and mechanism is key to identifying alternatives. Onglyza belongs to a class of oral medications called dipeptidyl peptidase-4 (DPP-4) inhibitors, which work to increase insulin production and regulate blood sugar.

Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are a popular class of oral medications for type 2 diabetes, often used as a second-line treatment after metformin. However, with several options available, determining which gliptin is best for diabetes requires a personalized assessment of a patient's health status, comorbidities, and specific treatment goals.